KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EPS (Weighted Average and Diluted) (2016 - 2025)

Biogen (BIIB) has 17 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.35 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 119.13% year-over-year to -$0.35; the TTM value through Dec 2025 reached $8.79, down 21.45%, while the annual FY2025 figure was $8.79, 21.38% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.35 in Q4 2025 per BIIB's latest filing, down from $3.17 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $7.77 in Q3 2022 and bottomed at -$0.47 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $2.96, with a median of $2.68 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 665.96% in 2024, then tumbled 119.13% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.5 in 2021, then soared by 52.0% to $3.8 in 2022, then crashed by 55.26% to $1.7 in 2023, then increased by 7.65% to $1.83 in 2024, then crashed by 119.13% to -$0.35 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.35 in Q4 2025, $3.17 in Q3 2025, and $4.33 in Q2 2025.